Innoviva Operating Income 2010-2023 | INVA

Innoviva operating income from 2010 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Innoviva Annual Operating Income
(Millions of US $)
2023 $114
2022 $474
2021 $375
2020 $321
2019 $246
2018 $238
2017 $184
2016 $109
2015 $32
2014 $-34
2013 $-29
2012 $-25
2011 $-110
2010 $-78
2009 $-81
Innoviva Quarterly Operating Income
(Millions of US $)
2023-12-31 $38
2023-09-30 $18
2023-06-30 $29
2023-03-31 $30
2022-12-31 $24
2022-09-30 $289
2022-06-30 $83
2022-03-31 $78
2021-12-31 $105
2021-09-30 $95
2021-06-30 $97
2021-03-31 $79
2020-12-31 $85
2020-09-30 $84
2020-06-30 $76
2020-03-31 $76
2019-12-31 $74
2019-09-30 $61
2019-06-30 $60
2019-03-31 $52
2018-12-31 $77
2018-09-30 $58
2018-06-30 $63
2018-03-31 $41
2017-12-31 $66
2017-09-30 $40
2017-06-30 $48
2017-03-31 $29
2016-12-31 $38
2016-09-30 $28
2016-06-30 $26
2016-03-31 $18
2015-12-31 $17
2015-09-30 $8
2015-06-30 $5
2015-03-31 $1
2014-12-31 $0
2014-09-30 $-10
2014-06-30 $-10
2014-03-31 $-15
2013-12-31 $19
2013-09-30 $-8
2013-06-30 $-7
2013-03-31 $-33
2012-12-31 $-30
2012-09-30 $-33
2012-06-30 $-36
2012-03-31 $86
2011-12-31 $-36
2011-09-30 $-29
2011-06-30 $-24
2011-03-31 $-21
2010-12-31 $-18
2010-09-30 $-20
2010-06-30 $-19
2010-03-31 $-21
2009-12-31 $-21
2009-09-30 $-21
2009-06-30 $-21
2009-03-31 $-18
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.959B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86